Can Mindfulness Actually Lower Your Blood Sugar? What the Evidence Really Shows
Written by Clare Koning, RN, PhD
Key Highlights
✅ Mindfulness-based interventions (MBIs) significantly reduced stress, depression, and anxiety in people with T2D
✅ MBIs reduced HbA1c by a mean of 0.44% across 9 trials (734 participants)
✅ MBIs improved HbA1c alongside large reductions in stress and anxiety
✅ Mindfulness-Based Cognitive Therapy (MBCT) showed strong glycemic effects
✅ The evidence is promising but not yet strong enough for formal clinical recommendations
Mindfulness has spent years hovering between genuine clinical tool and wellness trend, generating enthusiasm from some quarters and skepticism from others. For people living with type 2 diabetes, the relevant question has always been specific: does it actually do anything for blood sugar, stress, and quality of life, or is it simply feel-good medicine dressed in scientific language?
But let's first start with this. When last did you do absolutely nothing for 10 minutes?
Two systematic reviews and meta-analyses published in 2025 and 2026 give the most comprehensive and rigorous answer yet. The short version is: yes, mindfulness-based interventions appear to meaningfully reduce psychological distress in people with T2D, and they produce a modest but real reduction in HbA1c. The longer version requires some important caveats about evidence quality, which the researchers responsible for this work are admirably transparent about.
Here is what the evidence actually says.
What the 2025 Review Found
A systematic review and meta-analysis published in Integrative Medicine Research in March 2025, led by researchers at Western Sydney University and the University of Sydney, is the most comprehensive examination of mindfulness-based interventions for T2D conducted to date. The team searched five databases and two clinical trial registries, eventually including 31 randomized controlled trials involving 2,337 participants across Australia, China, Germany, India, Iran, the Netherlands, South Korea, Taiwan, Thailand, and the United States.
The interventions studied were diverse. Thirteen trials delivered Mindfulness-Based Stress Reduction (MBSR) or programs based on it, an eight-week program integrating mindfulness meditation, yoga-based embodiment practices, and psychological education about stress. Seven trials delivered Mindfulness-Based Cognitive Therapy (MBCT), which adds elements of cognitive behavioural therapy. The remainder delivered a range of other mindfulness approaches including mindful eating programs and adapted digital formats.
The psychological findings were substantial. Compared with waitlist control or usual care, MBIs significantly reduced:
Stress (SMD -1.01, 95% CI -1.91 to -0.20; 8 trials, 528 participants). This is a large effect size, though the certainty of the evidence was rated as very low due to high heterogeneity between trials.
Depression (SMD -1.26, 95% CI -2.08 to -0.43; 7 trials, 570 participants). Again, a large standardised effect with the same caveat about certainty.
Anxiety (SMD -0.67, 95% CI -1.27 to -0.08; 4 trials, 255 participants). A moderate effect, again rated as very low certainty.
On glycemic control, MBIs produced a mean HbA1c reduction of 0.44% (95% CI -0.71 to -0.17; 9 trials, 734 participants), rated as low certainty evidence.
In 31 randomized trials, mindfulness reduced stress, depression, and anxiety in people with T2D, and produced a mean HbA1c reduction of 0.44%. The psychological effects were large. The glycemic effect was modest but real.
A 0.44% reduction in HbA1c is clinically meaningful context. It sits in a similar range to some second-line diabetes medications, and is comparable to the HbA1c benefit seen with structured exercise programs. It is not trivial.
What the 2026 Meta-Analysis Added
A second, more recent meta-analysis published in Diabetes Research and Clinical Practice in July 2026 by researchers from Mae Fah Luang University in Thailand, drawing on nine electronic databases searched through May 2025, included 24 primary studies and 1,987 participants with diabetes.
The findings were consistent with the 2025 review and in some cases more encouraging. Across 24 primary studies, mindfulness-based interventions showed improvement of HbA1c (Hedges' g = 0.564, 95% CI 0.221 to 0.908, p = 0.001), stress (g = 1.132), anxiety (g = 1.321), and depression (g = 1.059). The HbA1c effect size of 0.564 in this analysis is notably larger than the 0.44% mean difference in the Western Sydney review, reflecting differences in study inclusion criteria, populations, and analytical approach.
A separate meta-analysis also published in 2025 which included 11 RCTs and 987 participants found that MBIs had effects at follow-up in reducing HbA1c levels (MD = -0.5, 95% CI -0.67 to -0.34) and depression (SMD = -0.84, 95% CI -1.11 to -0.56).
Across three independent meta-analyses now, the HbA1c signal lands in a narrow and consistent band: roughly 0.44% to 0.5% reduction, with the psychological effects consistently larger and more robust than the glycemic effects.
Why Does Mindfulness Affect Blood Sugar at All?
The mechanism connecting mindfulness practice to glycemic control is biologically plausible and involves at least three pathways, all documented in the 2025 review's discussion.
The most direct is the cortisol pathway. Chronic psychological stress elevates glucocorticoid levels, which stimulate hepatic glucose production through gluconeogenesis and impair insulin action in peripheral tissues. Mindfulness practice has been shown to reduce cortisol and catecholamine output, attenuating this glucose-raising hormonal response. As the Western Sydney authors note, "during periods of increased stress, glucocorticoid and catecholamine levels become elevated, which if unresolved in a timely manner, can disturb glucose homeostasis and can lead to chronic hyperglycemia."
The second pathway is behavioural. Reduced stress and depression improve adherence to self-care behaviours including medication-taking, dietary choices, sleep, and physical activity, all of which independently affect HbA1c. This indirect route may account for much of the glycemic benefit observed in the trials.
The third pathway involves sleep. MBIs have been shown to improve sleep quality, and sleep quality independently influences insulin sensitivity through the mechanisms discussed in a previous T2D Network blog. Better sleep, driven in part by reduced psychological stress, may represent another indirect route through which mindfulness influences blood sugar.
MBCT vs MBSR: Does the Type of Mindfulness Matter?
One of the more clinically interesting findings from the 2025 review concerns the difference between the two most commonly delivered mindfulness programs.
In subgroup analysis of HbA1c at the end of treatment, MBCT showed a significantly stronger glycemic effect than MBSR (MD -0.97%, 95% CI -1.33 to -0.61; 2 RCTs, 166 participants, very low certainty) compared with MBSR which did not significantly reduce HbA1c on its own (MD -0.31%, 95% CI -0.63 to 0.01; 4 RCTs, 411 participants).
This distinction matters practically. MBCT integrates cognitive behavioural elements alongside mindfulness meditation, which may be particularly relevant for people with T2D given the overlap between depressive cognition, diabetes burnout, and poor self-care motivation. The CBT component adds skills for identifying and reframing the negative thought patterns, such as "I've already blown my diet, what's the point," that drive self-management breakdown in T2D.
It is important to note that only two RCTs provided MBCT data for the HbA1c subgroup analysis, so this finding requires replication before firm clinical conclusions can be drawn.
What the Evidence Does Not Yet Show
The 2025 Western Sydney review is admirably honest about the limitations of the current evidence base, and those limitations are worth communicating directly.
The certainty of evidence across almost all outcomes was rated as very low to low using the GRADE approach. The primary reasons were high heterogeneity between trials (reflecting very different populations, settings, intervention formats, and comparison conditions), high risk of performance bias (participants cannot be blinded to whether they are doing mindfulness, creating expectation effects), and high rates of attrition across many studies.
Crucially, when MBIs were added to lifestyle interventions and compared against lifestyle alone, rather than usual care, no additional benefit was found for HbA1c or body weight. The review found "very low certainty evidence that MBIs + lifestyle may have no effect on HbA1c or body weight compared to lifestyle alone." This suggests that the glycemic benefit may operate largely through reducing the stress and psychological barriers that prevent people from implementing lifestyle changes in the first place, rather than through a direct metabolic mechanism operating independently of behaviour.
The review's conclusion is carefully worded and worth quoting directly: "MBIs may have clinical benefits (particularly psychological) for adults with T2DM, but lack of certainty in the evidence precludes clinical recommendations."
That is not a dismissal. It is an honest statement of where the evidence stands, which is further along than most people assume, but not yet at the level required for formal inclusion in clinical guidelines.
What This Means for People with T2D
Three things emerge from this evidence that are practically relevant right now.
The psychological benefits are the most robust finding and the most immediately applicable. If you are managing elevated stress, persistent low mood, or anxiety alongside T2D, and these are affecting your motivation to exercise, your eating patterns, or your medication adherence, a mindfulness program addresses all of those downstream effects through a single upstream intervention.
That is a clinically meaningful value proposition even before the blood sugar data is considered.
MBSR and MBCT are not the only options. The evidence includes digital and adapted programs, shorter formats, and group-based delivery. A feasibility study published in Complementary Therapies in Medicine found that a low-dose, eight-session MBSR program delivered in a clinical setting was feasible and acceptable for people with prediabetes and diabetes, suggesting that abbreviated formats may be viable for people who cannot commit to the standard eight-week program.
The time investment is real. Standard MBSR requires a meaningful commitment of time and, in some settings, financial cost. These are important considerations for clinicians and patients to weigh honestly. For some people, the available evidence may justify that investment. For others, it will not, and that is a legitimate clinical conversation.
What Should Be Next for This Research
The 2025 review authors are direct about what the field needs: larger trials with active control conditions that control for the attention effect of mindfulness programs, better reporting of session attendance and protocol fidelity, standardized outcome measures that allow comparison across studies, and longer follow-up periods to determine whether effects persist beyond the immediate post-intervention period.
A particular gap is the absence of adverse event reporting across all 31 included trials. Mindfulness interventions are generally low-risk, but temporary increases in anxiety or negative emotional experiences have been documented in some participants, and this deserves systematic reporting in future trials.
For more on the psychological dimensions of living with T2D, visit the T2D Network's Caregiver Support and Diabetes Stigma pages. For lifestyle management resources, visit Healthy Lifestyle.
